|
NEW
YORK, Feb. 16, 2005 (PRIMEZONE) -- Advance Nanotech,
Inc., (OTCBB:AVNA) has announced a joint venture with
Toumaz Technology Ltd. to bridge the gap between nanosystems
and the macroscopic world.
Bio-Nano Sensium Technologies,
the name of the joint venture, will utilize an intelligent,
ultra-low power sensor interface, incorporating wireless
communication, to create bio-nano sensors that can
be implanted within the body to diagnose and treat
a wide variety of medical conditions. The development
effort will focus on the information and communication
technology systems necessary for these sensors to
interact with their surrounding environment.
Development of the
sensor will leverage the many years of research in
ultra-low power circuits and systems at Imperial College
of Science, Technology and Medicine, London now exploited
by Toumaz Technology Ltd, in their proprietary Advanced
Mixed Signal "AMx" technology and wireless
transceiver devices. The Bio-Nano Sensium will be
capable of power consumption orders of a magnitude
lower than current state-of-the-art microprocessors.
This nano-power mode of operation is vital to the
longer lifetimes, reliability, and stability required
in biosensors, especially those that are implanted
within the body. The Bio-Nano Sensium will be based
on industry-standard Complementary Metal Oxide Semiconductor
(CMOS) technology so that not only will it have superior
functional features to other devices but also be capable
of low-cost production.
Keith Errey, CEO of
Toumaz Technologies stated, "We are very excited
about this joint venture. Toumaz has worked over the
past 4 years in developing a patented, low-power platform
technology and we are very pleased to be working with
Advance Nanotech to commercialize its use for the
next generation of medical devices in the high-value
bio-nano sector."
Commenting on the
joint venture, Magnus Gittins, CEO of Advance Nanotech,
Inc., said, "The Bio-Nano Sensium will play a
pivotal role in enabling truly personalized healthcare,
where continuous diagnosis can be matched to a treatment
program tailored to meet the needs of the individual
-- all within a small, implantable medical device.
Previous investments made by Toumaz Technology into
the platform technologies, which make the Bio-Nano
Sensium possible, take us well into the commercialization
process."
About Toumaz Technology
Ltd.
Toumaz Technology
Limited is a developer of advanced RF, analogue and
mixed signal semiconductors. The focus of the business
is low power devices based on the company's proprietary
AMx(tm) (Advanced Mixed Signal) technology which addresses
the needs of lower power consumption for mobile and
wirelessly connected systems.
About Advance Nanotech
Inc
Advance Nanotech,
Inc. (``Advance'') commercializes innovative nanotechnology.
Operating in three areas, electronics, biopharma and
materials, Advance leverages relationships with financial
and development resources to enable a product focused
fast-track commercialization of nanotechnology. Advance
has established relationships with academic institutions
throughout the world that are at the forefront of
nanotechnology research and development. Advance's
objective is to invest in patented innovation to bridge
early stage product development with valuable markets.
CONTACT: Advance Nanotech,
Inc. -- New York
Liza Mullins, (646) 723 8962
liza.mullins@advancenanotech.com
Advance Nanotech,
Inc. -- London
Charlotte Ramelli +44 (0) 207 451 2466
charlotte.ramelli@advancenanotech.com
Toumaz Technology
Ltd
Marie Grice +44 (0) 1235 438950
marie.grice@toumaz.com
|